- Home
- SELF vs NXTC Comparison
SELF vs NXTC Comparison
Compare SELF & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SELF | NXTC |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 49.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SELF | NXTC |
|---|---|---|
| Price | $5.03 | $11.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 43.8K | 28.6K |
| Earning Date | 11-07-2025 | 03-05-2026 |
| Dividend Yield | ★ 5.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $12,733,279.00 | N/A |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $31.38 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $4.73 | $2.69 |
| 52 Week High | $5.89 | $15.74 |
Technical Indicators
Market Signals| Indicator | SELF | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 41.38 |
| Support Level | $4.90 | $10.42 |
| Resistance Level | $5.15 | $11.49 |
| Average True Range (ATR) | 0.08 | 1.18 |
| MACD | -0.00 | -0.30 |
| Stochastic Oscillator | 60.42 | 22.16 |
Price Performance
Historical ComparisonAbout SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.